New Report: New Incentives for Physicians to Prescribe Biosimilars Would Improve Affordability

Friday, April 15, 2016 Research News J E 4

WASHINGTON, April 15, 2016 /PRNewswire-USNewswire/ -- Incentives for physicians to prescribe biosimilars could increase utilization and reduce costs, according to a new report — "Payor Strategies to Promote Biosimilar Utilization"— from Matrix Global Advisors (MGA) and released by the Pharmaceutical Care Management Association (PCMA).

The report notes that "Policymakers and payors could, in a manner similar to how some payors promote increased generic utilization, encourage physicians to use biosimilars, by rewarding them for doing so."

Click here to read the report.

"Each day providers delay prescribing FDA-approved biosimilars means higher costs and fewer options for patients," said PCMA President and CEO Mark Merritt.

"Biosimilars offer the potential to improve the cost-effectiveness of medicines by driving competition. But to facilitate a robust biosimilars marketplace in the U.S., additional tools may be necessary for payors to consider," said Alex Brill, CEO of MGA and author of the report.

The Food and Drug Administration (FDA) recently approved Inflectra, the second biosimilar approved in the United States. Inflectra will compete with Remicade to treat Crohn's disease and rheumatoid arthritis, among other conditions.

According to a recent IMS Health report, the amount of drug spending expected to be subject to biosimilar competition between 2016-2020 is $182 billion.

PCMA is the national association representing America's pharmacy benefit managers (PBMs).  PBMs administer prescription drug plans for more than 266 million Americans who have health insurance from a variety of sponsors including: commercial health plans, self-insured employer plans, union plans, Medicare Part D plans, the Federal Employees Health Benefits Program (FEHBP), state government employee plans, managed Medicaid plans, and others.

Follow PCMA on Twitter


To view the original version on PR Newswire, visit:

SOURCE Pharmaceutical Care Management Association



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
High Supply Initiates Racketeering Lawsuit Against...
Do You Speak The Right Bedroom Language?